| Revision as of 04:50, 22 May 2013 editLFaraone (talk | contribs)Edit filter managers, Administrators16,917 edits Reverted good faith edit(s) by Dclutz using STiki← Previous edit | Revision as of 03:36, 1 June 2013 edit undoDclutz (talk | contribs)11 edits Undid revision 556216027 by LFaraone (talk)Next edit → | ||
| Line 11: | Line 11: | ||
| }} | }} | ||
| '''Anthera Pharmaceuticals, Inc.''' is a |
'''Anthera Pharmaceuticals, Inc.''' is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases. Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, Immunoglobin A nephropathy, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.<ref name=10k>{{cite web|url=http://investor.anthera.com/secfiling.cfm?filingID=1214659-13-1633=Form 10-K, Anthera Pharmaceuticals, Inc.|date=March 26, 2012|publisher=U.S. Securities and Exchange Commission}}</ref> | ||
| ==Product Candidates== | ==Product Candidates== | ||
| Anthera has one drug in ] of clinical development, and two in ].<ref name=10k/><ref name=products>{{cite web|url=http://www.anthera.com/products_overview.asp|title=Product Cantidates: Overview|accessdate=August 4, 2011|publisher=Anthera Pharmaceuticals, Inc.}}</ref> | |||
| ⚫ | *], an investigational ] molecule in Phase III trails for the treatment of ] and Phase II trials for the treatment of IgA nephropathy. | ||
| *], an investigational ] agent for the treatment of ]. The drug was closed to study in March 2012, with patients taken off of it, with the company citing lack of effectiveness in the trials.<ref>{{cite news| url=http://www.bloomberg.com/news/2012-03-12/anthera-shares-plunge-on-stopping-heart-trial-for-lack-of-effectiveness.html | work=Bloomberg | first=Ryan | last=Flinn | title=Anthera Shares Plunge on Stopping Heart Trial for Lack of Effectiveness | date=March 12, 2012}}</ref> | |||
| ⚫ | *], an investigational ] molecule for the treatment of ]. | ||
| *], an investigational anti-inflammatory agent for the treatment of ]. | |||
| ==References== | ==References== | ||
Revision as of 03:36, 1 June 2013
 | |
| Company type | Public |
|---|---|
| Traded as | Nasdaq: ANTH |
| Industry | Pharmaceuticals |
| Founded | 2004 |
| Headquarters | Hayward, California, U.S. |
| Key people | Paul F. Truex (President and CEO) |
| Website | Anthera.com |
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases. Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, Immunoglobin A nephropathy, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.
Product Candidates
- Blisibimod, an investigational anti-BAFF molecule in Phase III trails for the treatment of systemic lupus erythematosus and Phase II trials for the treatment of IgA nephropathy.
References
- . U.S. Securities and Exchange Commission. March 26, 2012 10-K, Anthera Pharmaceuticals, Inc. http://investor.anthera.com/secfiling.cfm?filingID=1214659-13-1633=Form 10-K, Anthera Pharmaceuticals, Inc.
{{cite web}}: Check|url=value (help); Missing or empty|title=(help)
